1	Standardization and Age-Distribution of COVID-19: Implications for
2	Variability in Case Fatality and Outbreak Identification
3	
4	David N. Fisman MD MPH <sup>1</sup> , Amy L. Greer PhD MSc <sup>2</sup> , Ashleigh R. Tuite PhD MPH <sup>1,*</sup> ,
5	
6	<sup>1</sup> Dalla Lana School of Public Health, University of Toronto, Ontario, Canada
7	<sup>2</sup> Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada
8	
9	*Corresponding author:
10	David Fisman, MD MPH FRCP(C)
11	Room 686, 155 College Street
12	Toronto, Ontario, M5T 3M7
13	Email: david.fisman@utoronto.ca
14	
15	
16	Key words: COVID-19; transmission model; physical distancing; epidemic; public health
17	policy
18	
19	
20	
21	
22	Competing interests: none
23	
24	

### 25 Abstract

26

- 27 **Background:** Epidemiological data from the COVID-19 pandemic has
- 28 demonstrated variability in attack rates by age, and country-to-country
- 29 variability in case fatality ratio (CFR).
- 30 **Objective:** To use direct and indirect standardization for insights into the
- 31 impact of age-specific under-reporting on between-country variability in CFR,
- 32 and apparent size of COVID-19 epidemics.

33 **Design:** Post-hoc secondary data analysis ("case studies"), and mathematical

34 modeling.

- 35 **Setting:** China, global.
- 36 Interventions: None.

37 **Measurements:** Data were extracted from a sentinel epidemiological study by

38 the Chinese Center for Disease Control (CCDC) that describes attack rates and

39 CFR for COVID-19 in China prior to February 12, 2020. Standardized

40 morbidity ratios (SMR) were used to impute missing cases and adjust CFR.

41 Age-specific attack rates and CFR were applied to different countries with

42 differing age structures (Italy, Japan, Indonesia, and Egypt), in order to

43 generate estimates for CFR, apparent epidemic size, and time to outbreak

44 recognition for identical age-specific attack rates.

45 **Results:** SMR demonstrated that 50-70% of cases were likely missed during the

46 Chinese epidemic. Adjustment for under-recognition of younger cases decreased

- 47 CFR from 2.4% to 0.8% (assuming 50% case ascertainment in older
- 48 individuals). Standardizing the Chinese epidemic to countries with older
- 49 populations (Italy, and Japan) resulted in larger apparent epidemic sizes, higher

- 50 CFR and earlier outbreak recognition. The opposite effect was demonstrated for
- 51 countries with younger populations (Indonesia, and Egypt).
- 52 **Limitations:** Secondary data analysis based on a single country at an early
- 53 stage of the COVID-19 pandemic, with no attempt to incorporate second order
- 54 effects (ICU saturation) on CFR.
- 55 **Conclusion:** Direct and indirect standardization are simple tools that provide
- 56 key insights into between-country variation in the apparent size and severity of
- 57 COVID-19 epidemics.
- 58
- 59 **Funding:** The research was supported by a grant to DNF from the Canadian Institutes
- 60 for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

#### 62 Introduction

63

64 Knowledge and understanding related to COVID-19 are evolving rapidly, thanks 65 in no small part to outstanding epidemiological work done under challenging conditions in recent months (1). A report on 44,672 confirmed COVID-19 cases 66 67 from mainland China helped delineate early understanding of the outbreak's 68 epidemiology. More recent mathematical models help fill in some of the 69 informational gaps, by inferring the underlying processes, including the 70 occurrence of "silent", unrecognized infections, that must have driven this 71 epidemic (2). Modeling is an important tool for understanding epidemic 72 processes, but disease modeling expertise is not universally available. A much 73 more basic epidemiological tool (standardization) (3, 4) can be used to provide 74 important insights into both seen and unseen aspects of epidemics, and to 75 project the likely characteristics and impacts of the same epidemic process, if it 76 were to unfold in other populations.

77

78 We were struck by the absence of reported COVID-19 cases in younger 79 individuals in early reports from China. A pandemic disease is defined by the 80 novelty of the pathogen and absence of population-level immunity, such that all 81 age groups in a population should be equally susceptible to infection. Inasmuch 82 as more severe cases are more likely to be recognized, the under-recognition of 83 disease in younger individuals serves as a metric for differential disease severity 84 by age, and also provides important information that can be used to adjust case 85 fatality ratios for likely under-reporting. Furthermore, simple approaches to 86 quantify under-reporting can inform public health prevention strategies,

87 because if unrecognized cases are extremely common, control methods that

88 focus on identification of cases, isolation and quarantine alone are likely to fail.

89

- 90 We sought to use simple epidemiological tools, such as direct and indirect
- 91 standardization (i.e., calculation of standardized morbidity ratios) to gain
- 92 insights into likely disease under-reporting and case fatality in mainland China.
- 93 We then applied these insights to infer likely differences in disease severity
- 94 (based on CFR), and detection of epidemics occurring in countries *outside*
- 95 mainland China.

96

### 98 Methods

99

100 Data Sources

101

102	COVID-19 case counts by age were based on confirmed cases, by age, reported
103	in (5). 2020 country population projections for China by age were obtained from
104	the United Nations using the UNWPP package in R (6, 7). While the Chinese
105	COVID-19 epidemic was centered on the province of Hubei, the epidemic rapidly
106	spread to involve all Chinese provinces. Therefore, we used the total Chinese
107	population data by age to calculate age-specific cumulative incidence over the
108	initial 9 weeks of the epidemic. We used these initial observations to perform all
109	subsequent analyses.
110	

- 111 Standardized Morbidity Ratios
- 112

113 We calculated overall cumulative incidence per 100,000 population in the 66-114 days from December 8, 2019 (the date of onset in the first recognized human 115 COVID-19 case) to February 11, 2020 (8). Crude and age-specific cumulative 116 incidence were calculated as the ratio of case numbers to population size. 117 Standardized morbidity ratios (SMR) were then calculated as 100 x (observed 118 cases/expected cases) where expected cases are the product of crude 119 cumulative incidence and the population size of a given age group (4). 120 121

### 123 Under-Ascertainment of Younger Cases and Implications for Case-Fatality

124

125 Given that COVID-19 is an emerging communicable disease and there is no pre-126 existing immunity in the population, attack rates should be similar across age 127 groups, or possibly even higher in children due to their more intense contact 128 structure (9). The elevated SMR in older age groups, combined with their higher 129 case fatality, is suggestive of increased case ascertainment in this group due to 130 greater clinical severity. Indeed, when active case finding has been performed 131 for pediatric cases, attack rates in younger groups have been similar to those in 132 the older age groups. We examined a series of "case studies" where incidence in 133 older individuals (age > 59) was assumed to be measured accurately, and 134 cumulative incidence in older individuals was then applied to younger age 135 groups to generate estimates of the fraction of cases under-ascertained in these 136 age groups. We then revised the expected case fatality proportions based on 137 case counts adjusted for likely under-reporting in younger individuals. 138 139 Population Standardization, Case Fatality and Observed Outbreak Size 140 141 We evaluated the anticipated size, timing, and impact of an epidemic with 142 identical age-specific cumulative incidence and case fatality as observed in

143 China but applied to four countries outside of China. We standardized to144 countries and areas with older age than China (Japan, Italy) and younger age

- 145 (Indonesia, Egypt) as a means of isolating the impact of age structure on
- 146 outbreak characteristics. While somewhat arbitrary, these regions have all
- 147 either been impacted by COVID-19 to some degree (Japan, and Italy) (10-12);

148 have had large numbers of exported cases without large national epidemics 149 (Egypt)(13); or have been notable for the relatively limited number of cases 150 identified notwithstanding close links to China (Indonesia) (14). 151 152 Since China's large population size results in a far larger epidemic for a given 153 incidence, we used a ratio-of-ratio approach. The ratio of population in the 154 other, comparator country ( $P_0$ ) to the Chinese population ( $P_c$ ) was defined as  $R_P$ 155  $= P_0/P_c$ . The ratio of the observed epidemic size in the other, comparator 156 country (E<sub>0</sub>) to observed Chinese epidemic size (E<sub>c</sub>) was defined as  $R_E = E_O/E_C$ . 157 The ratio of ratios was thus  $R_E/R_P$ , and can be interpreted as the relative 158 apparent outbreak size when an outbreak with identical age-specific attack 159 rates occurs in a population with an age-structure that differs from that of 160 China. 161

162 Age Structure and Outbreak Detection

163

164 We estimated the incidence of observed infection among susceptible older

165 individuals (age > 59) in the Chinese population required for the observed

166 epidemic to have taken place over 66 days using the relation  $\lambda = -\ln(1-P)/t$ . This

167 hazard was then applied to 1) the Chinese population, and 2) the populations of

168 the other four "case study" countries, over a 66-day period under the

assumption that the most severe illness would be seen in those aged > 59 years.

170 We modeled time to observation of deaths by modeling time to symptoms,

171 severe pneumonia, ICU admission, and death using parameter estimates

172 presented in **Table 1**, assuming exponential failure time.

173

### 174 **Results**

175

176 Based on data in (8), the crude cumulative incidence of observed COVID-19 in 177 mainland China up until February 11, 2020 was 3.1 per 100,000. By contrast, 178 cumulative incidence in those aged > 59 years was 5.6 per 100,000. Age-179 specific cumulative incidence and SMR by age are presented in **Table 2** and 180 **Supplementary Figure 1**. It can be seen that SMR for age groups < 50 was 181 substantially lower than that in older age groups and most deaths were also 182 observed in older age groups (Table 2). When we assumed complete or near 183 complete ascertainment of cases in individuals aged >59, and adjusted 184 incidence in younger age groups accordingly, the adjusted CFR fell, and was 185 0.8% if we assume that only 50% of older cases were ascertained (Figure 1). 186 Even if all cases were ascertained in older individuals, it was estimated that 187 46% of total cases were missed; if only 50% of older cases were ascertained it 188 was estimated that 75% of cases were missed (Figure 1).

189

190 When the Chinese epidemic was age-standardized using population pyramids 191 from other countries, standardization to younger populations (Indonesia, Egypt 192 and Iran) markedly reduced CFR, while adjustment to older countries or regions 193 (Japan, Italy) elevated CFR (**Table 3**). The ratio-of-ratios,  $R_E/R_P$ , was less than 1 194 for countries with younger populations, but greater than 1 for countries with 195 older populations. In other words, apparent epidemics, adjusted for population 196 size, would be expected to be smaller in countries with younger populations

- 197 (shorter life expectancy) than in those with older populations (increased life
- 198 expectancy), even with identical age-specific attack rates.
- 199
- 200 When we simulated the mainland China epidemic in other countries, we found
- 201 that at any threshold of deaths required for outbreak detection, outbreaks
- 202 would be detected more quickly in countries with high life expectancy, and
- 203 more slowly in those with low life expectancy (Figure 2 and Online Appendix
- 204 (https://art-bd.shinyapps.io/time\_to\_outbreak\_detection/).
- 205
- 206

### 207 **Discussion**

208

209	As the COVID-19 pandemic has expanded its reach, the role of unrecognized
210	infection has received increased scrutiny (2, 15). While individuals with
211	unrecognized infection may be important in the epidemic's spread, those with
212	more severe illness are more likely to be recognized clinically, and more likely to
213	be referred for virological testing, a practice which the age distribution of
214	identified cases in China early in the pandemic, foretold (8).
215	
216	Age-related increases in severity, which may be confounded by increasing
217	prevalence of chronic medical conditions with age, are now well described in
218	countries outside China (16, 17). Greater recognition of individuals with more
219	severe illness, and undercounting of those with mild infection, is likely to inflate
220	apparent case fatality. While serological testing will ultimately help determine
221	the true infection fatality ratio for COVID-19, estimates of undercounting may
222	be derived if it is assumed that all in the population, regardless of age, are
223	equally vulnerable to infection. We demonstrate such an approach in this
224	paper.

225

The key driver of pandemic disease is a fully susceptible population; novel pathogens have higher reproduction numbers when they first emerge but the number drops once some proportion of the population has become immune (18). This leads to very high attack rates early in a pandemic. Furthermore, vulnerability to infection should be equally distributed across the population, with incidence expected to be highest in children, who have the highest rates

and intensity of person-to-person contact. As such, an absence of pediatric
cases in national reporting data represents an index of under-reporting rather
than immunity to infection and can be used as a means of quickly adjusting
models for under-reported fractions through simple, easily applied methods
such as direct and indirect standardization, which we employ here. Bayesian
methods provide a more computationally intensive and more technically
challenging approach to the same problem (2).

239

240 The extraordinary case-fatality in the COVID-19 pandemic (as high as 10-12%241 in Spain and Italy as of April 3, 2020) (19), also underscores the unusual 242 epidemiology of pandemics, since with endemic diseases (and some pandemics, 243 such as the 2009 (H1N1) influenza A pandemic) early life immune experience 244 protects those who would be vulnerable to severe disease conditional on 245 infection (i.e., older individuals), while permitting infection of younger 246 individuals less likely to experience severe disease (20). While case-fatality is 247 driven at least in part by the extent of testing, standardizing these epidemics to 248 different populations (in effect, letting an identical epidemic run out in a 249 different population) allows us to see that demographic structure alone can 250 explain many between country differences in apparent epidemic size and case 251 fatality. Adjusting for population size, identical epidemics will appear larger and 252 more severe in "older" countries (like those in Western Europe) and smaller and milder in "younger" countries (like Egypt, and Indonesia). 253

254

A key limitation of this work is that much of the work focusses on an epidemicin a single country, at an early point in the COVID-19 pandemic. Indeed, the

257 observable case-fatality in China now approximates 4%, rather than 2.4% as 258 reported earlier, which is likely to reflect lags between clinical onset and death 259 from COVID-19, especially in individuals who receive intensive care with 260 mechanical ventilation. We have, furthermore, not attempted to incorporate 261 second order effects, such as the resulting rapid saturation of ICU resources, 262 with resultant upwards inflection in case fatality, in countries with older 263 populations (e.g. Italy). Such effects may be operative in the devastating COVID-264 19 epidemics in Western Europe, which have CFR well beyond what our 265 standardization of the Chinese epidemic data would predict. 266 267 In conclusion, we find that standardization, both direct and indirect, provides a 268 simple, widely understood toolbox for explaining and understanding several of 269 the unusual features of COVID-19, including under-representation of pediatric 270 cases and geographic variability in apparent epidemic size and severity 271 (measured as CFR). While we are living in frightening and emotionally charged 272 times, we suggest that demographic variation, rather than misrepresentation 273 (21, 22), is likely to explain much of the between-country variability seen in the 274 current pandemic.

### 276 Figure Legends

277

### 278 Figure 1. Case Fatality and Fraction of Cases Missed Under Varying

### 279 Assumptions of Reporting Completeness in Older Individuals.

- 280 Estimates of the fraction of cases missed in the population as a whole (black
- solid curve), and true case-fatality ratio (CFR) (black dashed curve), as a
- 282 function of the fraction of cases missed in older adults who are assumed to be
- ascertained with the greatest accuracy. Decreasing case ascertainment in older
- adults implies an even higher fraction of cases are missed in the population as
- a whole, and CFR is lower than observed.
- 286

# Figure 2. Model Describing Differential Time To Recognition of COVID-19 Outbreaks in Countries with Different Age Structures.

Outbreaks with identical age-specific attack rates, and otherwise identical

289

290

characteristics, were simulated in countries with intermediate (China), old
(Italy) and young (Indonesia) populations. It can be seen that for any threshold
of deaths that must be exceeded for an outbreak to be recognized, older
countries will be identified before younger countries. Model details are as
described in the text.

296

# 297 Supplementary Figure 1. Observed Cumulative Incidence, Deaths and

### 298 Standardized Morbidity Ratios for Mainland China COVID-19 Epidemic.

299 Figure is a graphical representation of data presented in **Table 2**. SMR are

300 estimated as 100 x observed incidence divided by expected incidence, which in

- 301 the context of a pandemic is approximately equal in all age groups, or
- 302 somewhat higher in younger individuals.

304	References					
305						
306	1. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team,					
307	Qun L. An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei					
308	Province, 2019-2020. Available via the Internet at					
309	http://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-					
310	d057adb77b57. Last accessed January 25, 2020. China CDC Weekly.					
311	2020;2(5):79-80.					
312	2. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial					
313	undocumented infection facilitates the rapid dissemination of novel coronavirus					
314	(SARS-CoV2). Science. 2020.					
315	3. Standardization: a classic epidemiological method for the comparison of					
316	rates. Epidemiol Bull. 2002;23(3):9-12.					
317	4. Ginsberg GM, Tulchinsky TH, Salahov E, Clayman M. Standardized					
318	mortality ratios by region of residence, Israel, 1987-1994: a tool for public					
319	health policy. Public Health Rev. 2003;31(2):111-31.					
320	5. China Centers for Disease Control. Distribution of pneumonia in a new					
321	coronavirus infection. Available via the Internet at					
322	http://2019ncov.chinacdc.cn/2019-nCoV/. Last accessed February 3, 2020.					
323	6. United Nations Population Division. wpp2019: World Population					
324	Prospects 2019. R package version 1.1-1. https://CRAN.R-					
325	project.org/package=wpp2019. 2020.					
326	7. R Core Team. R: A language and environment for statistical computing. R					
327	Foundation for Statistical Computing, Vienna, Austria. URL <u>https://www.R-</u>					
328	<u>project.org/</u> . 2020.					

- 329 8. China Centers for Disease Control. Distribution of pneumonia in a new
- 330 coronavirus infection. Available via the Internet at
- 331 <u>http://2019ncov.chinacdc.cn/2019-nCoV/</u>. Last accessed February 3, 2020.
- 332 2020.
- 333 9. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al.
- 334 Social contacts and mixing patterns relevant to the spread of infectious
- diseases. PLoS Med. 2008;5(3):e74.
- 336 10. Omori R, Mizumoto K, Nishiura H. Ascertainment rate of novel
- 337 coronavirus disease (COVID-19) in Japan. medRxiv 2020030920033183; doi:
- 338 <u>https://doiorg/101101/2020030920033183</u> Last accessed April 5, 2020.
- 339 2020:
- 340
- 341 11. Guzzetta G, Poletti P, Ajelli M, Trentini F, Marziano V, Cereda D, et al.
- 342 Potential short-term outcome of an uncontrolled COVID-19 epidemic in
- 343 Lombardy, Italy, February to March 2020. Euro Surveill. 2020;25(12).
- 344 12. Tuite AR, Bogoch, II, Sherbo R, Watts A, Fisman D, Khan K. Estimation
- of Coronavirus Disease 2019 (COVID-19) Burden and Potential for International
- 346 Dissemination of Infection From Iran. Ann Intern Med. 2020.
- 347 13. Tuite AR, Ng V, Rees E, Fisman D, Wilder-Smith A, Khan K, et al.
- 348 Estimation of the COVID-19 burden in Egypt through exported case detection.
- 349 Lancet Infect Dis. 2020.
- 350 14. De Salazar P, Niehus R, Taylor A, Buckee C, Lipsitch M. Using predicted
- 351 imports of 2019-nCoV cases to determine locations that may not be identifying
- all imported cases. medRxiv 2020020420020495; doi:

- 353 <u>https://doiorg/101101/2020020420020495</u> Last accessed April 5, 2020.
- 354 2020.
- 355 15. Large scale testing of general population in Iceland underway. March 15,
- 356 2020. Available via the Internet at <u>https://www.government.is/diplomatic-</u>
- 357 <u>missions/embassy-article/2020/03/15/Large-scale-testing-of-general-</u>
- 358 <u>population-in-Iceland-underway/</u>. Last accessed April 5, 2020. Rejkavik,
- 359 Iceland: Iceland Ministry for Foreign Affairs; 2020 [
- 360 16. 2020 coronavirus pandemic in Spain. Available via Wikipedia at
- 361 https://en.wikipedia.org/wiki/2020\_coronavirus\_pandemic\_in\_Spain#cite\_note
- 362 <u>-es-covid-64-392</u>. Last accessed April 5, 2020. 2020 [
- 363 17. Sonnemaker T. New York City is the epicenter of the US coronavirus
- 364 outbreak here's how its death and hospitalization rates compare to the rest of
- 365 the country's. March 30, 2020. Available via the Internet at
- 366 <u>https://www.businessinsider.com/new-york-city-coronavirus-covid19-</u>
- 367 <u>outbreak-compared-united-states-2020-3#new-york-city-has-become-the-</u>
- 368 <u>epicenter-of-the-coronavirus-outbreak-in-the-us-4</u>. Last accessed April 5,
- 369 2020. Business Insider. 2020.
- 370 18. Pandemic Influenza Outbreak Research Modelling Team, Fisman D.
- 371 Modelling an influenza pandemic: A guide for the perplexed. CMAJ. 2009;181(3-
- 372 4):171-3.
- 373 19. BNO News. Tracking coronavirus: Map, data and timeline. Available via
- 374 the Internet at <u>https://bnonews.com/index.php/2020/02/the-latest-</u>
- 375 <u>coronavirus-cases/</u>. Last accessed February 29, 2020. 2020.
- 376 20. Greer AL, Tuite A, Fisman DN. Age, influenza pandemics and disease
- 377 dynamics. Epidemiol Infect. 2010;138(11):1542-9.

- 378 21. Courage K. The stark differences in countries' coronavirus death rates,
- 379 explained. April 1, 2020. Available via the Internet at
- 380 <u>https://www.vox.com/2020/4/1/21203198/coronavirus-deaths-us-italy-</u>
- 381 <u>china-south-korea</u>. Last accessed April 1, 2020. Vox. 2020.
- 382 22. Wadhams N, Jacobs J. China Concealed Extent of Virus Outbreak, U.S.
- 383 Intelligence Says. April 1, 2020. Available via the Internet at
- 384 <u>https://www.bloomberg.com/news/articles/2020-04-01/china-concealed-</u>
- 385 <u>extent-of-virus-outbreak-u-s-intelligence-</u>
- 386 says?utm\_source=twitter&utm\_content=politics&cmpid%3D=socialflow-twitter-
- 387 <u>politics&utm\_medium=social&utm\_campaign=socialflow-organic</u>. Last accessed
- 388 April 5, 2020. Bloombergcom. 2020.
- 389 23. Zhuang J, Cui H, Zhuang L, Zhai Z, Yang F, Luo G, et al. Bronchial
- 390 epithelial pyroptosis promotes airway inflammation in a murine model of
- 391 toluene diisocyanate-induced asthma. Biomed Pharmacother.
- 392 2020;125:109925.
- 393 24. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and
- 394 outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
- 395 China: a single-centered, retrospective, observational study. Lancet Respir Med.
- 396 2020.
- 397 25. Lauer S, Grantz K, Bi Q, Jones F, Zheng Q, Meredith H, et al. The
- 398 incubation period of 2019-nCoV from publicly reported confirmed cases:
- 399 estimation and application. Medrxiv 2020020220020016; doi:
- 400 <u>https://doiorg/101101/2020020220020016</u>. 2020.

- 401 26. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical
- 402 Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-
- 403 Infected Pneumonia in Wuhan, China. JAMA. 2020.

Parameter		Estimate	Reference
Proportions			
	Severe pneumonia	0.15	(23)
	ICU requirement with severe	0.20	(23)
	pneumonia		
	Death in ICU	0.62	(24)
Average durati	on (days)		
	Incubation period	6	(25)
	Time from onset to	7	(26)
	hospitalization		
	Time from hospitalization to	3	(26)
	ICU		
	Time from ICU admission to	25	(25)
	death		
Force of infecti	ion (λ)	8.44 x 10 <sup>-7</sup>	Calculated based
			on (5).

# Table 1. Parameters Used for Time-To-Death Estimates

**NOTE:** ICU, intensive care unit.

Age	Cases	Deaths	Case	Population	Cumulative Incidence*	SMR
Group			Fatality	(millions)		
0-9	416	0	0	170.7	0.24	7.9
10-19	549	1	0.002	166.6	0.33	10.6
20-29	3619	7	0.002	185.1	1.95	63.0
30-39	7600	18	0.002	228.8	3.32	107.0
40-49	8571	38	0.004	216.1	3.97	127.8
50-59	10008	130	0.013	222.2	4.50	145.1
60-69	8583	309	0.036	151.7	5.66	182.3
70-79	3918	312	0.080	71.5	5.48	176.6
80+	1408	208	0.148	26.6	5.29	170.4

# Table 2: Epidemiological Characteristics of China's COVID-19 Epidemic to February 11, 2020.

**NOTE:** SMR, standardized morbidity ratio.

\*per 100,000 population.

### Table 3: Direct Standardization of Mainland China's COVID-19 Epidemic

## to Other Countries and Regions

Country/Region	Country-	Epidemic	Population	$R_E/R_P$
	Standardized	Size Ratio	Size Ratio	
	CFR (%)	(R <sub>E</sub> )*	(R <sub>P</sub> )*	
Mainland China	2.3			
Egypt	1.6	0.05	0.07	0.69
Indonesia	1.7	0.15	0.19	0.81
Italy	3.9	0.05	0.04	1.15
Japan	4.4	0.10	0.09	1.18

**NOTE:** CFR, case fatality ratio.

\*Compared to Mainland China.





# Time (days)